The global anti-infective agents market is expected to reach over USD 111.4 billion by 2024 according to a new report by Grand View Research, Inc. The rising prevalence of infectious diseases such as HIV, H1N1, and Ebola virus reflect the profound changes in behavioral patterns of communities over the recent decades. The societal changes and the increasing awareness levels amongst the healthcare professionals and the patients pertaining to these diseases are driving the anti-infective agents market.
Organizations, such as the WHO and CDC are actively involved in spreading awareness amongst people regarding the implications of infectious diseases, which are fatal in nature and the importance of early treatment. The CDC has collaborated with the National Health Ministry (NHM) in an attempt to spread awareness and enhance the treatment rates for communicable diseases in developing countries such as Brazil, China, Nigeria, and India.
However, the introduction of novel therapeutics with increased potency and efficacy and the commercialization of pipeline products, such as commercialization of Omadacycline in 2018 for the treatment of Community Acquired Bacterial Pneumonia (CABP) in the near future, are expected to favorthe market growth.
View
summary of this report @ http://www.grandviewresearch.com/industry-analysis/anti-infective-agents-market
Further keyfindings from the study suggest:
·
The antibacterial segment was observed to
account for the largest share of over 54.0% in 2015. The large market share is
attributed to the fact that antibacterials are preferred as the first line of
treatment for a large range of infections, the high prescription rates exhibited
by this segment, and the increased accessibility of the antibacterials due to
their over-the-counter status.
·
The development of combination drugs to treat
and prevent, serious and life-threatening infections is expected to accentuate
the usage of anti-infective drugs. For instance, in 2012,
Gilead Sciences, Inc. launched Stribild, which is a comprehensive treatment
regimen inclusive of four drugs(cobicistat, elvitegravir, emtricitabine, and
tenofovir disoproxil fumarate) used for the treatment of HIV patients without
prior retroviral treatment record.
·
The anti-viral agents segment is expected to
grow at a swift CAGR of over 3.5% owing to the high price associated with the
introduction of new potent anti-viral drugs such as Vicriviroc for HIV
treatment purpose
·
North America dominated the overall
anti-infective agents market in terms of revenue of over25.0 billion in
2015.The rise in prevalence of infectious diseases including hospital-acquired
infections in both, children and adults, and the resultant overuse of
antibiotics coupled with the increased accessibility to non-prescription
anti-infectives in the market are the factors responsible for its
dominance.
·
Asia Pacific is one of the fastest growing
regional segments owing to the presence of high, unmet market demand for novel
drugs, rapid improvements in healthcare infrastructure coupled with the rising
awareness amongst healthcare professionals as well as patients
·
Some of the major companies operating in this market
are Abbott Laboratories, Gilead Sciences, Inc., Bristol-Myers Squibb Co., Merck
& Co., Inc, Bayer Healthcare AG, AstraZeneca Plc, Boehringer Ingelheim, and
Novartis AG.
·
Effective disease management involves a range of
long-term strategies such as new product development, merger and acquisitions,
co-development, and expansion. For instance, in 2015, ReViral has received a
funding of USD 21 million for the development of its RV521 drug by the Wellcome
Trust.
Browse
more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the anti-infective agents market on the basis of type and region:
Anti-infective agents market type outlook, by revenue (USD Million, 2014 - 2024)
·
Antibacterial
o
Cephalosporins
o
Penicillins
o
Fluoroquinolones
o
Macrolides
o
Carbapenems
o
Others
·
Antifungal
o
Azoles
o
Echinocandins
o
Polyenes
·
Antiviral
Anti-infective agents market regional outlook, by revenue (USD
Million, 2014 - 2024)
·
North America
·
U.S.
·
Canada
·
Europe
·
Germany
·
UK
·
France
·
Asia Pacific
·
Japan
·
India
·
China
·
Latin America
·
Brazil
·
Mexico
·
MEA
·
South Africa
For free press release of this report - http://www.grandviewresearch.com/press-release/global-anti-infective-agents-market
About Grand View
Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry
James
Corporate
Sales Specialist, U.S.A.
Grand
View Research, Inc.
United
States
Phone: 1-415-349-0058
Toll
Free: 1-888-202-9519
Email: sales@grandviewresearch.com
No comments:
Post a Comment